Novartis and Sandoz have reported new clinical data that demonstrates the safety and efficacy of their proposed biosimilar version of adalimumab.
Findings from a long-term study of patients continuously treated with the proposed biosimilar, which is based on AbbVie's Humira, showed that the drug was able to offer a similar performance to the original reference therapy throughout 51 weeks of treatment in patients with moderate to severe chronic plaque psoriasis.
“Novartis and Sandoz's new biosimilar adalimumab has been shown to match the reference biologic in terms of efficacy and safety in a long-term study.“
The new adalimumab biosimilar is currently under review by the European Medicines Agency for the treatment of several immunological diseases, and could represent an affordable new therapeutic option if approved.
Dr Mark Levick, global head of development of biopharmaceuticals at Sandoz, said: "Biosimilars are fundamentally changing the ability of healthcare systems to address this challenge. This clinical data supports the safety and efficacy of our proposed biosimilar adalimumab and offers a real alternative for patients living with immunological diseases."
Sandoz currently has five biosimilars on the market worldwide and plans to launch a total of five major oncology and immunology biosimilars between 2017 and 2020, including adalimumab.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical